BSE, Angel One Shares Slide Over 7% as SEBI Proposes Longer Tenure for Equity Derivatives

Shares of capital-market-linked firms including Bombay Stock Exchange (BSE) and Angel One Ltd witnessed sharp declines on Thursday, falling over 7% intraday, after the Securities and Exchange Board of India (SEBI) announced plans to recalibrate the tenure and maturity profile of equity derivative products. The move, aimed at improving market depth and promoting long-term investing, triggered immediate reactions from traders and investors concerned about its impact on short-term trading volumes.

Market Reaction: Sharp Selloff in Capital Market Stocks

BSE shares dropped as much as 7.44% to an intraday low of ₹2,335.20, down from the previous close of ₹2,523. The stock had opened higher but reversed course following SEBI Chairman Tuhin Kanta Pandey’s remarks at the FICCI Capital Market Conference 2025. Angel One also saw a steep decline, falling 7.01% to ₹2,530.15 before settling at ₹2,547.90.

  • BSE Market Cap: ₹94,768 crore
  • Angel One Market Cap: ₹72,430 crore
  • Trading Volume: Over 71 lakh shares exchanged on NSE for BSE alone

The selloff extended to other capital-market infrastructure firms such as CDSL, which also saw declines, reflecting broader concerns about regulatory changes affecting trading behavior.

SEBI’s Reform Agenda: Longer Tenure, Better Maturity

SEBI Chairman Tuhin Kanta Pandey stated that the regulator is exploring ways to extend the tenure and maturity of equity derivative contracts in a calibrated manner. The goal is to enhance the utility of derivatives for hedging and long-term investing, rather than speculative short-term trading.

“We will consult with stakeholders on ways to improve, in a calibrated manner, the maturity profile of derivative products so that they better serve hedging and long-term investing,” Pandey said during the conference.

The proposed reforms are part of SEBI’s broader strategy to strengthen the cash equities market and improve the quality and depth of derivatives trading. The regulator emphasized that while derivatives are vital for capital formation, their current structure may be skewed toward ultra-short-term speculation.

Why the Market Reacted Sharply

The equity derivatives segment has seen explosive growth in recent years, particularly among retail traders. According to SEBI’s own research:

  • 91% of individual traders in F&O incurred net losses in FY25
  • Over ₹1 lakh crore in retail capital was lost, which could have otherwise supported long-term investment and capital formation

SEBI’s move to extend derivative tenures is seen as a corrective measure to reduce speculative churn and promote more responsible trading. However, firms like BSE and Angel One, which benefit from high-frequency trading volumes, are expected to see short-term pressure on revenues and client activity.

Industry Perspective: Balancing Growth with Stability

Market experts believe SEBI’s proposal is a step toward aligning India’s capital markets with global standards, where longer-tenure derivatives are common and used for genuine hedging. However, the transition may require adjustments in trading platforms, investor education, and product design.

Angel One and BSE, both heavily reliant on retail participation and active trading volumes, may need to recalibrate their business models to accommodate a shift toward longer-term instruments.

Looking Ahead: What Investors Should Watch

While the immediate reaction has been negative, the long-term implications of SEBI’s reforms could be constructive for market stability and investor protection. Key developments to monitor include:

  • Stakeholder consultations and draft guidelines from SEBI
  • Changes in derivative contract structures and expiry cycles
  • Impact on brokerage revenues and trading platforms
  • Investor education initiatives to support the transition

Conclusion: Regulatory Reset Sparks Volatility, But Signals Maturity

The sharp dip in BSE and Angel One shares underscores the market’s sensitivity to regulatory shifts—especially those affecting trading volumes and product structures. SEBI’s push for longer-tenure equity derivatives is a bold step toward deepening India’s capital markets and curbing speculative excess.

While firms may face short-term headwinds, the move could pave the way for a more balanced, investor-friendly ecosystem that prioritizes sustainability over speed. For now, volatility may persist, but the direction signals a maturing market with stronger foundations.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com

India Cements Shares Surge 5% as UltraTech’s 6.5% Stake Sale via OFS Opens

Shares of India Cements Ltd rallied nearly 5% in early trade on Thursday after UltraTech Cement, its promoter and majority stakeholder, officially launched an Offer for Sale (OFS) to divest up to 6.49% of its holding in the company. The move is part of UltraTech’s strategy to comply with minimum public shareholding norms and streamline its ownership structure following last year’s acquisition.

India Cements stock opened higher at ₹374.05 and surged to ₹387.60 on the BSE, marking a 4.75% intraday gain. The rally lifted the company’s market capitalization to ₹11,850 crore, reflecting strong investor interest in the OFS and broader confidence in the cement sector’s recovery trajectory.

OFS Details: Strategic Stake Reduction by UltraTech

UltraTech Cement, which held an 81.49% stake in India Cements as of the June 2025 quarter, is offering to sell up to 2.01 crore equity shares, representing 6.49% of India Cements’ paid-up capital. The OFS will be conducted through the stock exchange mechanism, in accordance with SEBI regulations.

  • Floor Price: ₹368 per share
  • Offer Window: August 21 (non-retail investors), August 22 (retail investors and carry-forward bids)
  • Estimated Value of Sale: Over ₹740 crore

Post-sale, UltraTech’s stake will reduce to exactly 75%, aligning with SEBI’s mandate for minimum public shareholding in listed companies.

Background: UltraTech’s Acquisition and Strategic Moves

UltraTech Cement became the majority shareholder in India Cements following a series of strategic transactions in 2024:

  • July 2024: Acquired 32.72% stake from promoters and associates for ₹3,954 crore
  • Subsequent Open Offer: Announced ₹3,142 crore open offer to acquire an additional 26% from public shareholders
  • December 2024: Received approval from the Competition Commission of India (CCI) for the acquisition

These moves positioned UltraTech as the dominant player in India Cements, strengthening its footprint in the southern cement market and expanding its operational scale.

Market Reaction: India Cements Up, UltraTech Marginally Lower

While India Cements shares surged on the back of the OFS announcement, UltraTech Cement traded marginally in the red. The stock dipped 0.3% to ₹12,835 on the BSE, reflecting mild profit booking and investor focus on the divestment process.

Analysts noted that the OFS is unlikely to impact UltraTech’s long-term fundamentals, as the stake reduction is regulatory-driven and not indicative of strategic exit.

Operational Outlook: India Cements on Recovery Path

In its recent earnings call, UltraTech Cement’s CFO Atul Daga emphasized that India Cements is undergoing a transformation phase, with targeted capital expenditure aimed at improving efficiency and sustainability.

Key initiatives include:

  • Waste Heat Recovery Systems (WHRS)
  • Cooler upgrades and speed modifications
  • Alternate fuel technologies
  • Renewable energy expansion: From 3% to 86% of total power requirement by FY28

These projects are expected to reduce operating costs and enhance profitability, with most investments offering attractive payback periods.

Investor Perspective: Compliance, Clarity, and Confidence

The OFS not only helps UltraTech meet regulatory norms but also improves liquidity and public float in India Cements. For investors, this translates into:

  • Greater transparency in ownership
  • Improved governance standards
  • Enhanced trading volumes and price discovery

The timing of the OFS, amid a broader market rally and sectoral optimism, adds to its appeal for institutional and retail participants.

Conclusion: Strategic Realignment with Positive Market Sentiment

India Cements’ 5% surge reflects investor confidence in the company’s future under UltraTech’s stewardship. The OFS is a regulatory milestone, but also a signal of strategic maturity—balancing compliance with long-term growth.

As retail investors gear up for their participation window on August 22, market watchers will be keen to see how demand shapes up and whether the stock sustains its upward momentum.

For now, the cement sector continues to build strength—one strategic move at a time.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com

Stock Market Highlights: Sensex Extends Winning Streak to 6 Days, Nifty Tops 25,050; Pharma Stocks Lead Gains

Indian equity benchmarks continued their upward momentum for the sixth consecutive session on Thursday, supported by sustained buying in pharma, banking, and energy stocks. The BSE Sensex closed 142.87 points higher at 82,000.71, while the NSE Nifty gained 33.20 points to settle at 25,083.75, crossing the psychological 25,050 mark for the first time this week.

Market Overview: Strength Amid Sectoral Rotation

Despite mixed global cues and selective profit booking, domestic indices remained resilient. The rally was led by large-cap pharma stocks and private banks, while midcap and smallcap indices showed signs of fatigue after a strong three-day run.

  • Advancing stocks: 2,025
  • Declining stocks: 1,886
  • Unchanged: 145

The India VIX, which measures market volatility, declined over 3 percent to 11.37, indicating a stable trading environment and reduced investor anxiety.

Top Gainers: Pharma Stocks Outperform

Pharma stocks were the standout performers of the day. Cipla rose 3 percent, driven by strong quarterly earnings and positive sentiment around its product pipeline. Dr. Reddy’s Laboratories gained 2 percent, supported by robust export demand and margin expansion.

Other notable gainers included:

  • ICICI Bank
  • Bajaj Finserv
  • SBI Life Insurance

These stocks benefited from institutional buying and favorable sectoral outlooks.

Sectoral Performance: Mixed Trends

Gaining Sectors:

  • Pharma
  • Oil & Gas
  • Private Banks
  • Realty
  • Infrastructure
  • Information Technology

Declining Sectors:

  • FMCG
  • Auto
  • PSU Banks
  • Consumer Durables
  • Midcaps and Smallcaps

The divergence reflects a cautious approach by investors, with a preference for defensives and quality large-cap names.

Policy Developments: SEBI and GST in Focus

SEBI Chairman Tuhin Kanta Pandey, speaking at the FICCI Capital Market Conference, hinted at extending the tenure of equity derivatives. This move, if implemented, could reshape trading strategies and risk management practices.

Meanwhile, the Group of Ministers approved the Centre’s proposal for GST rate rationalisation, supporting a simplified two-slab structure. This reform is expected to boost consumption and improve compliance, particularly in the auto and consumer goods sectors.

Global Cues and Market Outlook

Global markets remained mixed amid geopolitical tensions and commodity price fluctuations. However, Indian equities showed resilience, supported by strong domestic fundamentals and policy clarity.

Key factors to watch in the coming sessions include:

  • US Federal Reserve commentary on interest rates
  • Crude oil price movements
  • Domestic macroeconomic data including GDP and inflation
  • Progress on GST reforms and SEBI’s regulatory updates

Conclusion: Momentum Intact, But Caution Advised

The sixth straight day of gains reflects investor confidence, but sectoral divergence and midcap weakness suggest a phase of consolidation. Pharma and private banks remain in favor, while auto and FMCG may face selective pressure until policy clarity improves.

With Nifty breaching 25,000 and Sensex holding above 82,000, the short-term trend remains positive. However, traders and investors are advised to stay cautious, manage risk, and rely on research-backed strategies—especially from SEBI-registered analysts who offer regulated, data-driven insights.

Eqwires Research Analyst

Top-notch SEBI registered research analyst

Best SEBI registered Intraday tips provider

info@eqwires.com

Telegram Facebook Instagram

Call: +91 9624421555 / +91 9624461555

www.eqwires.com